Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay.

Rios Perez, Mayrim V; Dai, Bingbing; Koay, Eugene J; Wolff, Robert A; Fleming, Jason B

Rios Perez, Mayrim V; Dai, Bingbing; Koay, Eugene J; Wolff, Robert A; Fleming, Jason B.

Afiliación

Rios Perez MV; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center ; General Surgery, University of Puerto Rico.
Dai B; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center.
Koay EJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center.
Wolff RA; Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center.
Fleming JB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center.

Cureus ; 7(12): e423, 2015 Dec 21.

Article en En | MEDLINE | ID: mdl-26848412

Palabras clave

curative surgery; ex-vivo chemosensitivity assay; folfirinox; metastatic pancreatic cancer; pancreaticoduodenectomy; stage iv pancreatic cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2015 Tipo del documento: Article